- ICH GCP
- Yhdysvaltain kliinisten tutkimusten rekisteri
- Kliininen tutkimus NCT05264493
Bioavailability Study of Naloxone 5 Milligrams (mg) Intramuscular (IM) Autoinjector
A PHASE 1 RANDOMIZED, OPEN-LABEL, SINGLE-DOSE, 3-TREATMENT CROSS-OVER STUDY TO EVALUATE RELATIVE BIOAVAILABILITY OF INTRAMUSCULAR INJECTION OF NALOXONE HCL 5 Milligrams (mg) [5mg/0.5 Milliliters (mL] USING A QUICKSHOT™ AUTOINJECTOR COMPARED TO 2 mg NALOXONE INTRAMUSCULAR INJECTION AND 2 mg NALOXONE INTRAVENOUS INJECTION IN HEALTHY ADULT PARTICIPANTS
Tutkimuksen yleiskatsaus
Tila
Ehdot
Yksityiskohtainen kuvaus
Opintotyyppi
Ilmoittautuminen (Todellinen)
Vaihe
- Vaihe 1
Yhteystiedot ja paikat
Opiskelupaikat
-
-
Connecticut
-
New Haven, Connecticut, Yhdysvallat, 06511
- New Haven Clinical Research Unit
-
-
Osallistumiskriteerit
Kelpoisuusvaatimukset
Opintokelpoiset iät
Hyväksyy terveitä vapaaehtoisia
Sukupuolet, jotka voivat opiskella
Kuvaus
Inclusion Criteria:
Participants are eligible to be included in the study only if all of the following criteria apply:
Age and Sex:
Healthy male and/or female participants of non-childbearing potential, who, at the time of screening, are between the ages of 18 and 55 years, inclusive.
Refer to protocol for reproductive criteria for male and female participants.
Type of Participant and Disease Characteristics:
- Male and female participants who are overtly healthy as determined by medical evaluation including medical history, physical examination, vital signs, 12-lead ECG, and/or clinical laboratory tests.
Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
Weight:
- BMI of 17.5 to 30.5 kg/m2; and a total body weight > 50 kg (110 lb).
Informed Consent:
5. Capable of giving signed informed consent as described in Appendix 1, which includes compliance with the requirements and restrictions listed in the ICD and in this protocol.
-
Exclusion Criteria:
Participants are excluded from the study if any of the following criteria apply:
Medical Conditions:
- Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
- Current or past diagnosis of any type of drug dependence within the past year will not be eligible to participate. History of alcohol abuse, dependence or binge drinking and/or any other illicit drug use within 6 months of screening. Binge drinking is hours. As a general rule, alcohol intake should not exceed 14 units per week (1 unit = 8 ounces (240 mL) beer, 1 ounce (30 mL) of 40% spirit or 3 ounces (90 mL) of wine).
- If fever is present within 7 days of admission or screening.
- Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurological, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
- History of HIV infection, hepatitis B, or hepatitis C, positive testing for HIV, HBsAg, or HCVAb. Hepatitis B vaccination is allowed.
Other medical or psychiatric condition including recent (within the past year) or active suicidal ideation/behavior or laboratory abnormality that may increase the risk of study participation or, in the investigator's judgment, make the participant inappropriate for the study.
Prior/Concomitant Therapy:
- Use of prescription or nonprescription drugs and dietary and herbal supplements within 14 days or 5 half-lives (whichever is longer) prior to the first dose of study intervention. Prior/Concurrent Clinical Study Experience:
Previous administration with an investigational drug within 30 days (or as determined by the local requirement) or 5 half-lives preceding the first dose of study intervention used in this study (whichever is longer).
Diagnostic Assessments:
- A positive urine drug test.
- Has participated in, is currently participating in, or is seeking treatment for substance-and/or alcohol-related disorders (excluding nicotine and caffeine).
- Has a positive alcohol breathalyzer test at screening or upon admission to the study center of Treatment Period. Positive results may be repeated and/or participants re-scheduled at the investigator's discretions.
- Screening supine BP ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), following at least 5 minutes of supine rest. If BP is ≥140 mm Hg (systolic) or ≥90 mm Hg (diastolic), the BP should be repeated 2 more times and the average of the 3 BP values should be used to determine the participant's eligibility. Repeated BP tests should be spaced at least 5 minutes apart.
- Screening supine 12-lead ECG demonstrating a QTc interval > 450 msec or a QRS interval > 120 msec. If QTc exceeds 450 msec, or QRS exceeds 120 msec, the ECG should be repeated 2 more times and the average of the 3 QTc or QRS values should be used to determine the participant's eligibility.
Participants with ANY of the following abnormalities in clinical laboratory tests at screening, as assessed by the study-specific laboratory and confirmed by a single repeat test, if deemed necessary:
Abnormal platelet count and/or PT/INR; AST or ALT level ≥1.5 × ULN; Total bilirubin level ≥1.5 × ULN; participants with a history of Gilbert's syndrome may have direct bilirubin measured and would be eligible for this study provided the direct bilirubin level is ≤ ULN.
Other Exclusions:
- Blood donation (excluding plasma donations) of approximately 1 pint (500 mL) or more within 60 days prior to dosing.
- History of sensitivity to heparin or heparin-induced thrombocytopenia.
- Unwilling or unable to comply with the criteria in the Lifestyle Considerations section of this protocol.
- History of hypersensitivity to naloxone or any of the components in the formulation of the study products.
Investigator site staff or Pfizer employees directly involved in the conduct of the study, site staff otherwise supervised by the investigator, and their respective family members.
-
Opintosuunnitelma
Miten tutkimus on suunniteltu?
Suunnittelun yksityiskohdat
- Ensisijainen käyttötarkoitus: Perustiede
- Jako: Satunnaistettu
- Inventiomalli: Crossover-tehtävä
- Naamiointi: Ei mitään (avoin tarra)
Aseet ja interventiot
Osallistujaryhmä / Arm |
Interventio / Hoito |
---|---|
Kokeellinen: naloxone 5 mg IM autoinjector
participants will receive in random order, a single naloxone 5 mg IM autoinjector injection into the lateral thigh
|
5 mg (5 mg/0.5 mL) IM autoinjector injection into lateral thigh
|
Active Comparator: naloxone 2 mg IM
participants will receive in random order, a single naloxone 2 mg IM injection into the gluteus muscle
|
2 mg IM (2mg/2 mL) injection into gluteal muscle
2 mg bolus IV (2mg/2 mL)
|
Active Comparator: naloxone 2mg bolus IV
participants will receive in random order, a single naloxone 2 mg bolus IV injection
|
2 mg IM (2mg/2 mL) injection into gluteal muscle
2 mg bolus IV (2mg/2 mL)
|
Mitä tutkimuksessa mitataan?
Ensisijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
Maximum observed plasma naloxone concentration (Cmax) of a single 5 mg IM autoinjector injection compared to a 2 mg IM injection
Aikaikkuna: predose, 2.5, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1440 minutes after dose
|
Comparison of bioavailability
|
predose, 2.5, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1440 minutes after dose
|
Area under the naloxone concentration versus time curve (AUC) from time zero to the last collection time (AUClast) of a single 5 mg IM autoinjector injection compared to a 2 mg IM injection
Aikaikkuna: predose, 2.5, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1440 minutes after dose
|
Comparison of bioavailability
|
predose, 2.5, 5, 10, 15, 30, 45, 60, 90, 120, 180, 240, 360, 480, and 1440 minutes after dose
|
Toissijaiset tulostoimenpiteet
Tulosmittaus |
Toimenpiteen kuvaus |
Aikaikkuna |
---|---|---|
AUC from time zero to 2.5 minutes (AUC0-2.5)
Aikaikkuna: predose and 2.5 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose and 2.5 minutes after dose
|
AUC from time zero to 5 minutes (AUC0-5)
Aikaikkuna: predose, 2.5 and 5 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5 and 5 minutes after dose
|
AUC from time zero to 15 minutes (AUC0-15)
Aikaikkuna: predose, 2.5, 5, 10 and 15 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10 and 15 minutes after dose
|
AUC from time zero to 30 minutes (AUC0-30)
Aikaikkuna: predose, 2.5, 5, 10, 15, and 30 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10, 15, and 30 minutes after dose
|
AUC from time zero extrapolated to infinity (AUCinf) [if data permit]
Aikaikkuna: predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Time to maximum observed naloxone plasma concentration (Tmax) [if data permit],
Aikaikkuna: predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Time for naloxone plasma concentration to decrease by one half (t1/2) [if data permit].
Aikaikkuna: predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Pharmacokinetics all treatment arms
|
predose, 2.5, 5, 10, 15, 30, 60,90, 120, 180, 240, 360, 480, 1440 minutes after dose
|
Number of participants with a clinically significant change from baseline physical examination
Aikaikkuna: baseline to 28 days after last dose
|
Safety and tolerability all treatments
|
baseline to 28 days after last dose
|
Number of participants with a clinically significant change from baseline vital signs
Aikaikkuna: baseline to 28 days after last dose
|
Safety and tolerability all treatments
|
baseline to 28 days after last dose
|
Number of participants with a clinically significant change from baseline clinical safety laboratory measurements
Aikaikkuna: baseline to 28 days after last dose
|
Safety and tolerability all treatment arms
|
baseline to 28 days after last dose
|
Number of participants with clinically significant AEs from baseline
Aikaikkuna: baseline to 28 days after last dose
|
Safety and tolerability all treatment arms
|
baseline to 28 days after last dose
|
Yhteistyökumppanit ja tutkijat
Sponsori
Julkaisuja ja hyödyllisiä linkkejä
Hyödyllisiä linkkejä
Opintojen ennätyspäivät
Opi tärkeimmät päivämäärät
Opiskelun aloitus (Todellinen)
Ensisijainen valmistuminen (Todellinen)
Opintojen valmistuminen (Todellinen)
Opintoihin ilmoittautumispäivät
Ensimmäinen lähetetty
Ensimmäinen toimitettu, joka täytti QC-kriteerit
Ensimmäinen Lähetetty (Todellinen)
Tutkimustietojen päivitykset
Viimeisin päivitys julkaistu (Todellinen)
Viimeisin lähetetty päivitys, joka täytti QC-kriteerit
Viimeksi vahvistettu
Lisää tietoa
Tähän tutkimukseen liittyvät termit
Avainsanat
Muita asiaankuuluvia MeSH-ehtoja
Muut tutkimustunnusnumerot
- C2431001
Yksittäisten osallistujien tietojen suunnitelma (IPD)
Aiotko jakaa yksittäisten osallistujien tietoja (IPD)?
IPD-suunnitelman kuvaus
Lääke- ja laitetiedot, tutkimusasiakirjat
Tutkii yhdysvaltalaista FDA sääntelemää lääkevalmistetta
Tutkii yhdysvaltalaista FDA sääntelemää laitetuotetta
Nämä tiedot haettiin suoraan verkkosivustolta clinicaltrials.gov ilman muutoksia. Jos sinulla on pyyntöjä muuttaa, poistaa tai päivittää tutkimustietojasi, ota yhteyttä register@clinicaltrials.gov. Heti kun muutos on otettu käyttöön osoitteessa clinicaltrials.gov, se päivitetään automaattisesti myös verkkosivustollemme .
Kliiniset tutkimukset NaxRedy ™
-
BaroNova, Inc.Valmis
-
Medtronic CardiovascularMedtronicValmisAortan ahtaumaUusi Seelanti, Yhdistynyt kuningaskunta, Australia
-
London Health Sciences CentreUniversity of Western Ontario, Canada; Synaptive MedicalTuntematonAivovaurio, krooninen | Cerebellar Cognitive Affective Syndrome | Pikkuaivojen mutismi
-
Boston Scientific CorporationValmisOhimenevä iskeeminen hyökkäys | Tromboembolinen aivohalvaus | Aivohalvauksen ehkäisyYhdysvallat, Argentiina, Saksa
-
CereVasc IncAlvaMed, Inc.; Simplified Clinical Data Systems, LLC; Bioscience Consulting...RekrytointiVesipää | Vesipää, kommunikoivaArgentiina
-
Gülçin Özalp GerçekerValmisKatetrin komplikaatiot | Katetrin vuotoTurkki
-
Medtronic CardiovascularAktiivinen, ei rekrytointiAortan laajentumaSaksa, Uusi Seelanti, Yhdysvallat, Alankomaat, Sveitsi, Yhdistynyt kuningaskunta, Espanja, Australia, Italia, Ruotsi, Ranska, Itävalta, Slovakia
-
Andrew ParrentUniversity of Western Ontario, Canada; Synaptive MedicalTuntematonOhimolohkon epilepsia
-
Asklepios Kliniken Hamburg GmbHUniversity of KielValmisIlmateiden hallinta | Kurkunpään maski Airway | Kuituoptinen intubaatio
-
GlaxoSmithKlineValmisJäykkäkouristus | Kurkkumätä | Soluton hinkuyskä | Poliomyeliitti | Haemophilus Influenzae Tyyppi bKorean tasavalta